Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Thorough QT/QTc Study of TAS-205 in Healthy Male Adults
jRCT2071230127Phase 1Completed
- Sponsor
- Taiho Pharmaceutical Co., Ltd.
- Start
- May 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of pizuglanstat (4 arms), sponsored by Taiho Pharmaceutical Co., Ltd. Primary endpoints: Treatment-emergent adverse events (TEAEs), Treatment-related adverse events (TRAEs) and 1 more. Started May 2024; status: completed.
02
Drugs
pizuglanstat
Beyond the preview
Go deeper on jRCT2071230127.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2071230127.